Health ❯Healthcare ❯Pharmaceuticals ❯Drug Approval

Alzheimer's Treatment

France Blocks Early Access to Alzheimer’s Drug Leqembi for Now

The health regulator says the trial benefit is too small to justify early availability.

NICE Poised to Reject NHS Coverage for Breakthrough Alzheimer’s Drugs

Leqembi Approved by European Regulators for Early-Stage Alzheimer's Treatment

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs